SEINE BIO · PEPTIDE PROFILE

Elamipretide / SS-31

Mitochondrial medicine · a specific Barth syndrome indication

Approved product

Get to know the name, understand the evidence, and prepare a more informed conversation.

What is Elamipretide / SS-31?

Forzinity received accelerated FDA approval for improving muscle strength in patients with Barth syndrome weighing at least 30 kg. This specific approval does not establish general anti-aging or energy benefits. Source & further reading.

THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026

Inside the science of Elamipretide / SS-31.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.

Overview

Elamipretide is also known in research discussions as SS-31. The prescription medicine Forzinity has a specific accelerated approval related to muscle strength in Barth syndrome. Its mitochondrial research interest is broader, but a rare-disease approval should not be transformed into a general anti-aging, athletic-performance or energy-treatment claim.

Community Use

PeptideDosages and Peptidepedia describe SS-31 in informal and longevity contexts. Those publisher accounts differ from Forzinity’s prescribing information and trial population. A shared molecule name does not make research material, formulations or use goals equivalent.

Doses, Durations & Cycles

Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.

Protocol reference — Elamipretide / SS-31
Route / formulation	Dose / reported phases	Frequency	Duration / break	Notes and source
Subcutaneous	40 mg daily for patients weighing at least 30 kg; adult severe renal impairment: 20 mg daily	Daily	Barth syndrome treatment; no fixed cycle Break: No routine cycling interval	FDA prescribing information FORZINITY

Important context: This approved formulation and indication do not validate anti-aging use of a research vial.

Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.

The table separates the approved daily regimen from informal source claims. Forzinity’s label includes patient-weight criteria and renal considerations. These details require a specialist’s interpretation and cannot be replaced by a general “mitochondrial support” cycle drawn from a community source.

Research Findings

FDA’s trial snapshot explains the evidence supporting approval. The setting is Barth syndrome, not healthy adults seeking improved exercise performance. The approval rests on an intermediate muscle-strength endpoint, so the nature of the measured benefit and confirmatory obligations matter.

U.S. Approval & Access

Forzinity’s 2025 accelerated approval applies to qualifying Barth syndrome patients weighing at least 30 kg. Continued approval may depend on confirmatory benefit. DailyMed lists DEA Schedule: None. This status does not authorize every SS-31 product or a general longevity prescription pathway.

What It Does in the Body

The label characterizes elamipretide as a mitochondrial cardiolipin binder. The biological target helps explain the research program but does not diagnose the cause of fatigue. Reliable onset, peak benefit and duration of a general wellness effect have not been established. Trial follow-up is not proof of an enduring response after stopping.

Benefits & Reported Experiences

Barth syndrome findings should remain attached to the disease, study design and strength measurements used. They do not establish a predictable energy boost in a person without that diagnosis. When reading an anti-aging claim, ask whether the quoted result actually measured function, health outcomes or only a biological marker.

Side Effects & Risks

Forzinity’s label includes hypersensitivity concerns and injection-site reactions. A rare-disease development program cannot answer every safety question about broader informal use or combinations. The actual patient’s renal function, diagnosis and concurrent care are relevant to risk, even when mitochondrial targeting sounds more selective than other drug mechanisms.

Delivery Options

The approved route is subcutaneous administration of the labeled prescription product. Community discussion of a similarly named vial is not a substitute for the device, formulation or instructions used in care. This article provides no preparation, injection technique or route-substitution advice.

Product Quality & Storage

The label requires refrigeration at 2–8°C, no freezing and discarding the vial eight days after first opening under its permitted conditions. These are Forzinity-specific instructions. An unofficial SS-31 material cannot inherit that product’s stability, sterility or shelf life merely by using the same molecular name.

Combinations & Interactions

An SS-31 combination with NAD+, MOTS-C or another longevity-related material is a distinct intervention with its own unanswered questions. The Barth syndrome approval does not validate that stack. This page does not provide combination timing or infer enhanced safety from a shared mitochondrial theme.

Talking With Your Provider

Persistent fatigue or weakness warrants assessment for its actual cause. If Barth syndrome is relevant, a specialist should guide care. Otherwise, discuss established diagnostic and treatment options and the limits of mitochondrial research. A clinician conversation can be useful without promising elamipretide or attributing every symptom to mitochondrial dysfunction.

Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.

Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.

Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.

Questions worth bringing to your appointment.

Are there alternatives that address my goal?
If treatment is appropriate, what monitoring and follow-up would I need?
Could my health history or current medicines change the risks?

A clinician may recommend a different option—or no medication—after assessing your individual circumstances.

Saved discussion topics 0

Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.

Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.

Bring your curiosity. Start a conversation.

Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.

Create a free account ↗

This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.

Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.

Bring your saved topics to your care team.

Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.

Choose saved topics for review →